PDGFRA non-D842V exon 18 mutations in GIST are imatinib-SENSITIVE (distinct from D842V)....
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-PDGFRA-EXON18-NON-D842-GIST |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-GIST |
| Quellen | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-PDGFRA |
|---|---|
| Variante | exon 18 non-D842V mutation (e.g., D846Y, N848K, Y849K, deletion DIM842-844) |
| Erkrankung | DIS-GIST |
| ESCAT-Stufe | IB |
| Empfohlene Kombinationen | imatinib 400 mg/day (1L advanced/metastatic non-D842V exon 18 PDGFRA), avapritinib (alternative; investigational) |
| Zusammenfassung der Beweise | PDGFRA non-D842V exon 18 mutations in GIST are imatinib-SENSITIVE (distinct from D842V). Imatinib 400 mg/day is standard 1L — responses comparable to KIT exon 11 GIST. Avapritinib also active. Genotyping is mandatory to distinguish D842V (avapritinib) from non-D842V exon 18 (imatinib-first). |
Anmerkungen
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST. Adjuvant imatinib applies in high-risk resected non-D842V PDGFRA GIST (3 yr).
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.